Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeWearable DevicesValeritas ENABLE Study Demonstrates Significant Clinical Benefits of V-Go in Patients with...

Valeritas ENABLE Study Demonstrates Significant Clinical Benefits of V-Go in Patients with Type 2 Diabetes Who Switched from Insulin Pens and Syringes

Data Presented at Annual ADA Meeting Reports Patients with Type 2 Diabetes who Switched to V-Go® had Significant Improvement in Blood Glucose and Used Less Insulin.

MARKET REPORTS

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets – ResearchAndMarkets.com

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts – ResearchAndMarkets.com

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device—a simple, all-in-one, wearable insulin delivery option for patients with diabetes—announced today positive results from the EffectiveNess of V-Go WeArable Insulin Delivery for Basal-BoLus ThErapy (ENABLE) Study.

Three poster presentations at the American Diabetes Association Meeting in Orlando, Florida, reported that patients who switched from insulin pens and syringes to V-Go significantly improved blood glucose while lowering insulin dose.

Valeritas CEO, John Timberlake, commented, “The largest study of V-Go patients to date has demonstrated that regardless of baseline insulin dose or duration of diabetes, patients who switched to V-Go significantly lowered their blood glucose.  We believe that is significant for diabetes patients, their medical professionals, payors, and Valeritas.”

Mr. Timberlake continued, “We recently reported our third consecutive quarter of record revenue which is a direct result of V-Go gaining momentum among patients with type 2 diabetes.  V-Go is discreet, simple-to-use, cost-effective, clinically proven, and the only disposable, daily insulin delivery option.”

[socialpug_tweet tweet=”Valeritas CEO, John Timberlake, commented, “The largest study of V-Go patients to date has demonstrated that regardless of baseline insulin dose or duration of diabetes, patients who switched to V-Go significantly lowered their blood glucose. We believe that is significant for diabetes patients, their medical professionals, payors, and Valeritas.”” display_tweet=”” style=”3″]

Poster 988 – EffectiveNess of V-Go WeArable Insulin Delivery for Basal-BoLus ThErapy (ENABLE) Study: A Multicenter Retrospective Real World Evaluation in Type 2 Diabetes.

The first ENABLE Study poster evaluated the clinical benefits in patients with type 2 diabetes who switched from using insulin pens and syringes to deliver their insulin regimen with V-Go for insulin delivery. The 283 patient, retrospective study demonstrated clinically and statistically significant reductions in A1C by over 1% (a measure of blood glucose control), and insulin total daily dose (TDD) at three and seven months. The percent of patients at high risk (A1C > 9%) was reduced by nearly 50% after switching to V-Go.  In addition, over 50% of all patients in the study achieved an A1C less than 8%.

“We categorize patients with an A1C above 9.0% as high risk since they are more likely to have long-term complications that impact health care costs. The significant reduction in A1C and the achievement in A1C goals after switching to V-Go in the ENABLE study has important implications for treating diabetes. By improving glycemic control, our hope is to reduce rates of complications as well as decrease health care cost, which is a priority for all healthcare systems.” said lead author and endocrinologist Ripu Hundal, M.D., of First State Endocrinology in Newark, Delaware.

After three and seven months of V-Go use, significant reductions were observed in both A1C (-1.01 and -1.04; p<0.0001) and TDD (-17 U/day and -14 U/day; p<0.0001).

Poster 989 – Achievement of Glycemic Targets when Switching from Basal-Bolus Therapy to V-Go for Insulin Delivery in Type 2 Diabetes.

The second analysis from the ENABLE study confirmed V-Go provided a clinical benefit in a patient population poorly controlled on conventional basal-bolus therapy delivered by multiple daily injections (MDI) using insulin pens and syringes.

The analysis in 186 patients with type 2 diabetes demonstrated lowering of A1C by -1.0 at three months which was sustained at seven months and statistically significant with a P<0.0001. Insulin TDD was reduced by 30% (84 U/day to 59 U/day) with V-Go use. To determine if TDD was a factor in the change in A1C, patients were separated into three approximately equal groups based on baseline TDD (< 60 U/day [mean of 46 U/day], 60 to 90 U/day [mean of 72 U/day], or > 90 U/day [mean of 134 U/day]).  Results demonstrated statistically significant A1C reductions across all TDD groups of -1.0, -0.8, -1.2, respectively, each with a P<0.001.

Poster 990 – Clinical Outcomes with V-Go in Type 2 Diabetes based on Duration of Diabetes.

The third ENABLE study poster evaluated the impact of duration of diabetes on change in A1C and insulin TDD when switching patients with type 2 diabetes from insulin delivery via insulin pen or syringe to V-Go. Patients with known duration of diabetes were stratified into five groups based on duration of diabetes (years).  Clinically and statistically significant reductions in A1C from baseline at both three and seven-month intervals were observed in all five duration of diabetes strata. All strata also benefited from reductions in TDD with the exception of the duration stratum with the lowest baseline TDD (15 to 20 years), which maintained similar dosing on V-Go compared to baseline.

“Findings from the ENABLE Study demonstrated that no matter how long a patient had been diagnosed with diabetes, switching to V-Go from insulin delivery via insulin pens and syringes resulted in significantly lower A1C levels,” said lead author, Jane Cases, M.D., of Marietta, Ohio. “We believe this positive data demonstrates that diabetes duration should not be a factor when determining which patient can benefit from using V-Go.”

spot_img

DON'T MISS

Children Achieve Time in Range Mirroring Well-controlled Adults for the 1st Time in Real-world Study of the MiniMed™ 780G System

"These results are extremely encouraging. Glycemic control has been much harder to achieve in children due to unpredictable factors common in this age group, including physical growth and development, hormonal changes and active lifestyles.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy